NNNN - CIK 0001982708
Anbio Biotechnology trades as NNNN and has a market capitalization of $1.50 B, making it the #2317 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $8.65M, up 5.6% from the prior year and net income of $6.40M. This page tracks Anbio Biotechnology through 40 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from 42.5% to 74.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-19 |
| 6-K | - | 2026-04-27 |
| 20-F/A | - | 2026-04-09 |
| New insider ownership | 3 | 2026-04-08 |
| New insider ownership | 3 | 2026-04-08 |
| New insider ownership | 3 | 2026-04-08 |
| New insider ownership | 3 | 2026-04-08 |
| New insider ownership | 3 | 2026-04-08 |
The largest companies sharing Anbio Biotechnology's SEC industry classification (in vitro & in vivo diagnostic substances).
Anbio Biotechnology (NNNN) has a market capitalization of $1.50 B as of 2026-05-29, ranking #2317 among US-listed companies.
Anbio Biotechnology reported revenue of $8.65M for fiscal year 2025, an increase of 5.6% year over year.
Yes. Anbio Biotechnology reported net income of $6.40M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.